A Full-Length Plasmodium falciparum Recombinant Circumsporozoite Protein Expressed by Pseudomonas fluorescens Platform as a Malaria Vaccine Candidate
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Full-Length Plasmodium falciparum Recombinant Circumsporozoite Protein Expressed by Pseudomonas fluorescens Platform as a Malaria Vaccine Candidate
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 9, Pages e107764
Publisher
Public Library of Science (PLoS)
Online
2014-09-24
DOI
10.1371/journal.pone.0107764
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8+ T Cells
- (2013) S. L. Baldwin et al. JOURNAL OF IMMUNOLOGY
- A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age
- (2013) Alphonse Ouédraogo et al. PLoS One
- Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant
- (2013) John J. Treanor et al. VACCINE
- Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults
- (2013) C Buddy Creech et al. Human Vaccines & Immunotherapeutics
- Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines
- (2012) Christopher B. Fox et al. Clinical and Vaccine Immunology
- Full-Length Plasmodium falciparum Circumsporozoite Protein Administered with Long-Chain Poly(I·C) or the Toll-Like Receptor 4 Agonist Glucopyranosyl Lipid Adjuvant-Stable Emulsion Elicits Potent Antibody and CD4+T Cell Immunity and Protection in Mice
- (2012) Kathrin Kastenmüller et al. INFECTION AND IMMUNITY
- A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults
- (2012) Michael C. Keefer et al. PLoS One
- A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E
- (2012) Francis M. Ndungu et al. PLoS One
- Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guérin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice
- (2012) Charles Arama et al. VACCINE
- KSAC, a Defined Leishmania Antigen, plus Adjuvant Protects against the Virulence of L. major Transmitted by Its Natural Vector Phlebotomus duboscqi
- (2012) Regis Gomes et al. PLoS Neglected Tropical Diseases
- GLA-SE, a Synthetic Toll-like Receptor 4 Agonist, Enhances T-Cell Responses to Influenza Vaccine in Older Adults
- (2011) Hayedeh Behzad et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and efficacy of the RTS,S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial
- (2011) Kwaku Poku Asante et al. LANCET INFECTIOUS DISEASES
- Reliable protein production in a Pseudomonas fluorescens expression system
- (2011) Diane M. Retallack et al. PROTEIN EXPRESSION AND PURIFICATION
- Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate
- (2011) Hillarie Plessner Windish et al. VACCINE
- The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert
- (2010) K. Radosevic et al. Clinical and Vaccine Immunology
- Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice
- (2010) Takayuki Shiratsuchi et al. JOURNAL OF CLINICAL INVESTIGATION
- A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
- (2010) Rhea N. Coler et al. PLoS One
- Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations
- (2009) Ryan C. Anderson et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Heterologous prime–boost vaccination
- (2009) Shan Lu CURRENT OPINION IN IMMUNOLOGY
- Structure of thePlasmodium falciparumCircumsporozoite Protein, a Leading Malaria Vaccine Candidate
- (2009) Matthew L. Plassmeyer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Protection against a Malaria Challenge by Sporozoite Inoculation
- (2009) Meta Roestenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- The development of the RTS,S malaria vaccine candidate: challenges and lessons
- (2009) W. R. BALLOU PARASITE IMMUNOLOGY
- Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice
- (2008) Joseph P. Shott et al. VACCINE
- The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity
- (2008) Silayuv E. Bongfen et al. VACCINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now